Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Telix Pharmaceuticals ( (AU:TLX) ).
Challenger Limited has filed a notice with the ASX confirming that it and its associated entities have ceased to be a substantial holder in Telix Pharmaceuticals Ltd, meaning their voting power has fallen below the substantial holding threshold. The change, formalised in a statutory Form 605 lodged on 23 January 2026, signals a reduction in Challenger’s equity exposure to Telix and may slightly alter Telix’s shareholder base composition, though no additional details on the nature or consideration of the transactions were disclosed.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$11.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Challenger Limited is an Australian-based financial services group that operates through multiple licensed entities, with a focus on retirement and investment products, life insurance, investment management, mortgage management, and securitisation services across major Australian capital cities.
Average Trading Volume: 1,907,280
Technical Sentiment Signal: Sell
Current Market Cap: A$3.89B
Learn more about TLX stock on TipRanks’ Stock Analysis page.